Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

Summary

RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial to study the effectiveness of epratuzumab in treating patients who have non-Hodgkin's lymphoma.

Timeline

Start

2002-05

Primary completion

—

Completion

—

Drugs

Indications